Federated Hermes
JBIO

Federated Hermes’s Jade Biosciences JBIO Stock Holding History

Federated Hermes’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-244
Closed -$22.6K – 2064
2024
Q4 		$22.6K Buy
244
+93
+62% +$8.01K ﹤0.01% 1760
2024
Q3 		$11K Buy
151
+129
+586% +$8.32K ﹤0.01% 1800
2024
Q2 		$1.29K Buy
22
+20
+1,000% +$13.3K ﹤0.01% 1936
2024
Q1 		$1.77K Buy
+2
New +$1.53K ﹤0.01% 1929
2023
Q2 		– Sell
-6
Closed -$4.07K – 2101
2023
Q1 		$4.07K Buy
6
+4
+200% +$3.32K ﹤0.01% 1952
2022
Q4 		$2.46K Buy
+2
New +$1.45K ﹤0.01% 1992

Other funds holding JBIO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
AI
Allostery Investments Stamford, Connecticut $7.85M AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes's JBIO Position: Q1 2025 in Review

Federated Hermes sold out of Jade Biosciences (JBIO) in Q1 2025, closing a stake of 244 shares — an estimated $22.6K sold.

Federated Hermes first reported a position in JBIO in Q4 2022 and held it in 6 quarters. The position peaked at $22.6K in Q4 2024. 78 funds tracked by Wall St. Rank hold JBIO as of Q1 2025.

  • Federated Hermes reported no remaining Jade Biosciences position as of Q1 2025 after selling out during the quarter.
  • Federated Hermes sold 244 Jade Biosciences shares in Q1 2025, an estimated $22.6K.
  • Federated Hermes first reported a position in Jade Biosciences in Q4 2022 and held it in 6 quarters.
  • Federated Hermes's Jade Biosciences position peaked at $22.6K in Q4 2024.
  • 78 funds tracked by Wall St. Rank held Jade Biosciences as of Q1 2025.

Based on Federated Hermes's 13F filing for Q1 2025, filed 8 May 2025.